Synaptogenix Inc (SNPX)

[SF Wolf]

F1ash, that is a very important catch: “a DMC may review unblinded study information (on a patient level or treatment group level) during the conduct of the study."

And your observation: “Obviously they can't share specifics, but I definitely see it within the realm of possibility that they might be able to provide some subtle clues to management.”

Also, the potential of Byrostatin being used in ERs worldwide for stroke treatment would be another massive market for NTRP if the drug is approved for that use.